Medicenna Therapeutics (MDNA) Stock Price, News & Analysis

Company Overview

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.

Key Stats

• Today's Range: C$1.67 to C$1.72
• 50-Day Range: C$1.45 to C$2.51
• 52-Week Range: C$0.38 to C$2.98
• Volume: 30,199 shs
• Average Volume: 103,197 shs
• Market Capitalization: C$130.70 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

MDNA Stock Analysis - Frequently Asked Questions

How have MDNA shares performed this year?

Medicenna Therapeutics' stock was trading at C$0.42 at the beginning of the year. Since then, MDNA shares have increased by 307.1% and is now trading at C$1.71.
View the best growth stocks for 2024 here.

How do I buy shares of Medicenna Therapeutics?

Shares of MDNA stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What other stocks do shareholders of Medicenna Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Medicenna Therapeutics investors own include Manulife Financial (MFC), Gilead Sciences (GILD), OPKO Health (OPK), Air Canada (AC), Athersys (ATHX), Birchcliff Energy (BIR) and Canadian Natural Resources (CNQ).

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: TSE:MDNA
• CUSIP: N/A
• CIK: N/A
• Web: www.medicenna.com
• Phone: +1-403-6807898
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): C($0.38)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: C$-26,240,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -105.43%
• Return on Assets: -32.80%

Debt

• Debt-to-Equity Ratio: 0.06
• Current Ratio: 2.51
• Quick Ratio: 4.65

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: C$1.49 per share
• Price / Cash Flow: 1.15
• Book Value: C$0.30 per share
• Price / Book: 5.70

Miscellaneous

• Outstanding Shares: 76,430,000
• Free Float: N/A
• Market Cap: C$130.70 million
• Optionable: Not Optionable
• Beta: 1.21